Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl
BRIDGEWATER, NJ – JUNE 7, 2022: Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,291,628 for Welchol® Chewable Bar, the Company’s novel drug delivery system of Colesevelam that is easy to handle and ingest, which provides patent protection until 2037.
Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format
Bridgewater, NJ and Vadodara, India May 24, 2022/PRNewswire/Cosette Pharmaceuticals, Inc ("Cosette"), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (“Alembic”; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva® (Docosanol cream 10%) in a 2 gm tube and pump formats. Shipments of the product will begin imminently.
Cosette Pharmaceuticals Launches First Injectable Product – Prochlorperazine Edisylate Injection in the U.S.
Cosette Pharmaceuticals, Inc., a New Jersey-based pharmaceutical company, today announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).
Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo
Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that it has closed a transaction to acquire the US sales and distribution rights to eight branded commercial products from leading Japanese pharmaceutical company, Daiichi Sankyo Company, Ltd (4568:JP) and affiliates.
Mindy Hanna has joined Cosette Pharmaceuticals as Senior Director, Human Resources
We are pleased to announce Mindy Hanna has joined Cosette Pharmaceuticals as Senior Director, Human Resources. Mindy will report to Apurva Saraf and will be based in the South Plainfield office.
Solaris Pharma Receives Approval for First Generic Version of Clindagel® (clindamycin phosphate EQ 1%)
Solaris Pharma Corporation (“Solaris” or the “Company”) announced today that the Company has received an abbreviated new drug application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA” or “Agency”) for the first generic version of Clindagel® (clindamycin phosphate EQ 1%). This product will be manufactured in the United States by Cosette, Solaris’ manufacturing partner. The product will be launched immediately.
Cosette Pharmaceuticals, Inc. Announces FDA Approval of ANDA for Hydrocortisone Valerate Cream USP, 0.2%
Cosette Pharmaceuticals, Inc., a New Jersey-based specialty generic pharmaceutical company, has received a first cycle approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Hydrocortisone Valerate Cream USP, 0.2%. This is Cosette’s first approval for 2021 from its internally-developed pipeline of prescription pharmaceutical products.
Cosette Pharmaceuticals Appoints Seasoned Industry Executive Apurva Saraf as President and Chief Executive Officer
We are very pleased to welcome Apurva to the Cosette team. His deep knowledge of the pharmaceutical industry, along with his corporate strategy and business development experience, will be of great value as Cosette continues to expand its portfolio of differentiated complex products, both internally and through strategic collaborations,” stated Sriram Venkataraman, Partner of Avista Capital Partners.
